The treatment of adolescents and young adults

Cancer is a rare condition in those aged between 13 and 25 years. It is, therefore, important to recognise the special situation of patients in this age group being treated for malignant disease (educational, work-related, physiological, psychological and social) and to tailor treatment accordingly.   

In 2002, the Department of Childhood and Adolescent Oncology established the first unit for adolescents (13-20 years) with cancer, known as « La Montagne » (The Mountain).

Department heads

The Paediatric Department team

The doctors are all qualified in general paediatric oncology and are able to stand in for one another without problems. Each one has, however, developed a specialist area of expertise in the management of specific types of tumour.  

Treatment of children and adolescents

1 child in 440 in France is affected by cancer. This is the most common cause of death by disease in those aged less than 15 years. The proportion of patients cured continues to increase: the cancer cure rate is 80% and enormous advances have been made.

Description

A department dedicated to Phase I clinical trials at Gustave Roussy, the Department of Therapeutic Innovation and Early Stage Trials (DITEP) aims to offer patients in therapeutic failure access to innovative molecules and accelerate the development of new cancer treatments. It has been accredited by the Institut National du Cancer as a Centre de Phase Précoce (CLIP²), and is authorized by the Agence Régionale de Santé to conduct Phase I trials.

Lab members

Team leader: Anne Dupressoir

Researchers :

• Anne DUPRESSOIR, CRHC Inserm
• Odile HEIDMANN, CRCN CNRS
• Thierry HEIDMANN, DREM
• Gérard PIERRON, DREM
• Marianne MANGENEY, CRHC CNRS
• Agathe BACQUIN, Researcher
• Grégoire MARTIN, Researcher
• Guillaume MOUSSEAU, Researcher
• Baptiste ROELENS, Researcher
• Jhen TSANG, Researcher
• Maude MARCHAIS, Researcher

ITA :

Publications

Endogenous retroviral envelopes / syncytin genes

Mousseau G, Préault N, Souquère S, Bireau C, Cassonet P, Bacquin A, Beck L, Pierron G, Jacob Y, Dupressoir A, and Heidmann T. The sodium dependent phosphate transporter PiT1/Slc20a1 is the receptor for the endogenous retroviral envelope syncytin-B involved in mouse placenta formation. J Virol 2024 Sep 17 e0091524  Editor's Pick
 

Physiology and Molecular Pathology of Endogenous and Infectious Retroviruses

This team belongs to the UMR 9196 : Physiology and Molecular Pathology of Endogenous and Infectious Retroviruses

The Unit's work, historically focused on retroelements and retroviruses, has made significant contributions to: